By the Doktorly editorial team · Medically reviewed by the Doktorly medical team · Last updated: 1 November 2026
Semaglutide is the active ingredient behind several branded medications – and the reason the "weight-loss injection" became globally famous. Understanding the molecule helps you put the headlines into context: what does the ingredient do, and how do Ozempic, Wegovy and the tablet Rybelsus differ?
Semaglutide is a GLP-1 receptor agonist: it mimics the gut hormone GLP-1, which after eating triggers satiety, slows gastric emptying and helps regulate insulin. It was developed by Novo Nordisk. Because the molecule was chemically modified so that it stays active for about a week, a single weekly injection is sufficient.
The higher-dosed Wegovy is the version officially intended for obesity and overweight with weight-related conditions.
For the weight-management indication the data is strong: in STEP 1, participants on 2.4 mg semaglutide weekly lost on average about 15 % of their starting weight over 68 weeks. In addition, the SELECT study showed a reduced cardiovascular risk in patients with overweight and pre-existing heart disease. For the diabetes approvals (SUSTAIN trials), good results for blood glucose and weight are documented as well.
Semaglutide is prescription-only. A prescription is only considered after a medical review – at Doktorly, for example, via an online first consultation in which indication, pre-existing conditions and current medication are checked. The prescription is then issued by licensed doctors and dispensed by a regular pharmacy. Purchase offers without medical review are neither legal nor safe.
They contain the same active ingredient at different doses. Ozempic is approved for type 2 diabetes, Wegovy for weight management – for losing weight, Wegovy is the approved variant.
Yes – as Wegovy, which is approved precisely for that. Ozempic, by contrast, would be off-label use, possible only after medical consideration.
Satiety and appetite effects often appear within the first two weeks. Pronounced weight loss develops over several months as the dose increases.
Depending on brand and dose, roughly 300 to 480 € per month for self-payers. Insurance reimbursement is only possible for the approved indication and subject to conditions.